维普期刊资源整合服务平台（V6.5）

51篇 您的检索式：作者名="Hurvitz SA"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in pa- tients with human epidermal growth factor receptor 2-positive meta- static breast cancer显示文摘	Hurvitz SA Dirix L Kocsis J	2013	J Clin Oncol2013，31，9：	1
2	Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hedgkin lymphoma 显示文摘	Ansell SM Hurvitz SA Koenig PA	2009	Clin Cancer Res2009，15，20：	1
3	Successful treatment with cyclophosphamide of life-threatening diffuse hemangiomatosis involving the liver显示文摘	Hurvitz SA Hurvitz CH Sloninsky L		0，，：	1
4	Phase Q randomized study of tras-tuzumab emtansine versus trastuzumab plus docetaxel in patients withhuman epidermal growth factor receptor 2-positive metastatic breastcancer显示文摘	Hurvitz SA Dirix L Kocsis J	2013	J Clin 0ncol2013，31，9：	1
5	Profiling and targeting HER2-posi-tive breast cancer using trastuzumab emtansine 显示文摘	Sadeghi S Olevsky O Hurvitz SA	2014	PharmgenomicsPers Med2014，7，：	1
6	Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma 显示文摘	Ansell SM Hurvitz SA Koenig PA	2009	Clin Cancer Res2009，15，20：	1
7	The facioaudio-symphalangism syndrome: report of a case and review of the literature显示文摘	Goodman RM Hertz M	1985	Clin Genet1985，28，：	1
8	A phase II trial of docetaxel with bevaeizumab as first-fine therapy for HER2 negative metastatic breast eancer(TORI B01)显示文摘	Hurvitz SA Allen HJ Moroose RL etal	2010	Clin Breast Cancer2010，10，4：	1
9	The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer:latest evidence and ongoing studies显示文摘	Hurvitz SA Kakkar R	2012	Ther Adv Med Oncol2012，4，5：	1
10	Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma显示文摘	Ansell SM Hurvitz SA Koenig PA	2009	Clin Cancer Res2009，15，20：	1
11	Recent advances in the devel- opment of anti-HER2 antibodies and antibody-drug conjugates 显示文摘	Wong D J Hurvitz SA	2014	Ann Transl Med2014，2，12：	1
12	In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response显示文摘	HURVITZ SA KALOUS O CONKLIN D	2015	Breast Cancer Res Treat2015，149，3：	1
13	Antibody-drug conjugates:an emerging modality for the treatment of cancer显示文摘	LEAL M SAPRA P HURVITZ SA	2014	Ann N Y Acad Sci2014，1321，：	1
14	Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions显示文摘	Hurvitz SA Pietras RJ	2008	Cancer2008，113，9：	1
15	What's positive about 'triple-negative' breast cancer?显示文摘	Hurvitz SA Finn RS	2009	Future Oncol2009，5，：	1
16	Ado-trastuzumab emtansine(T-DM1)in human epidermal growth factor receptor2(HER2)-positive metastatic breast cancer:latest evidence and clinical potential显示文摘	Peddi PF Hurvitz SA	2014	Ther Adv Med Oncol2014，6，5：	1
17	Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer显示文摘	Hurvitz SA Dirix L Koesis J	2013	J Clin Oncol2013，31，9：	1
18	Recent advances in the development of anti- HER2 antibodies and antibody-drug conjugates 显示文摘	Wong D J Hurvitz SA	2014	Ann Transl Med2014，2，12：	1
19	Current approaches and future directions in the treatment of HER2-positive breast cancer显示文摘	Hurvitz SA Hu Y O'Brien N	2013	Cancer Treat Rev2013，39，3：	1
20	A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER - 2 - overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy显示文摘	Hurvitz SA Dalenc F Campone M	2013	Breast Cancer Res Treat2013，141，3：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示